Spyre Therapeutics is emerging as a key player in inflammatory bowel disease, with a focus on pathway-specific monoclonal antibodies for superior disease control. The company has a healthy balance ...

Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report)’s stock price rose 6.6% during trading on Friday after the company announced better than expected quarterly earnings. The company ...

Looking for a complete list of Monster Hunter Wilds monsters? The best way for any hunter to prepare for a trip to the Forbidden Lands is to get familiar with all the monsters that call it home.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

WALTHAM, Mass. (AP) — WALTHAM, Mass. (AP) — Spyre Therapeutics, Inc. (SYRE) on Thursday reported a loss of $56.3 million in its fourth quarter. The Waltham, Massachusetts-based company said it ...

Reports Q4 revenue $0, consensus $2.1M. As of December 31, 2024, Spyre had cash, cash equivalents, and marketable securities of $603.1M. “In 2024, we initiated first-in-human studies for three ...